Bariatric Surgery and Pharmacokinetics of Methylphenidate

Norwegian University of Science and Technology1 enrolled

Overview

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on methylphenidate.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Obesity, Morbid

Interventions

MethylphenidateDRUG

Patients are tested for their normal prescription methylphenidate medication

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract

Locations (1)

St. Olavs University Hospital

Trondheim, Norway

Outcomes

Primary Outcomes

Methylphenidate concentration in blood serum (area under curve (AUC))

Time frame: From baseline to 1 year postoperatively

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.